Laureate Pharma, Inc. has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. Alopexx’s mAb F598 antibody will now be manufactured by Laureate under the agreement. The antibody is intended to be used for the treatment and prevention of Staphylococcus aureus infections.